Cingulate (NASDAQ:CING – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($1.48) per share for the quarter.
Cingulate Price Performance
CING stock opened at $3.78 on Friday. The company has a 50 day moving average price of $4.19 and a 200 day moving average price of $4.42. Cingulate has a fifty-two week low of $1.80 and a fifty-two week high of $20.83. The stock has a market capitalization of $14.24 million, a PE ratio of -0.26 and a beta of -0.87.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on CING shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Cingulate in a research report on Thursday, March 6th. Roth Capital raised Cingulate to a “strong-buy” rating in a research report on Friday, January 10th. Finally, Roth Mkm assumed coverage on Cingulate in a research note on Friday, January 10th. They set a “buy” rating and a $12.00 price objective on the stock.
Cingulate Company Profile
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
Recommended Stories
- Five stocks we like better than Cingulate
- What is a Low P/E Ratio and What Does it Tell Investors?
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- What is a Secondary Public Offering? What Investors Need to Know
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- Using the MarketBeat Dividend Yield Calculator
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
